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Background: Macrophages, which are CD4 and CCR5 positive, can sustain HIV-1 replication for long periods of
time. Thus, these cells play critical roles in the transmission, dissemination and persistence of viral infection. Of note,
current antiviral therapies do not target macrophages efficiently. Previously, it was demonstrated that interactions
between CCR5 and gp120 stimulate PKC. However, the PKC isozymes involved were not identified.
Results: In this study, we identified PKC-delta as a major cellular cofactor for HIV-1 replication in macrophages.
Indeed, PKC-delta was stimulated following the interaction between the virus and its target cell. Moreover,
inhibition of PKC-delta blocked the replication of R5-tropic viruses in primary human macrophages. However, this
inhibition did not have significant effects on receptor and co-receptor expression or fusion. Additionally, it did not
affect the formation of the early reverse transcription product containing R/U5 sequences, but did inhibit the
synthesis of subsequent cDNAs. Importantly, the inhibition of PKC-delta altered the redistribution of actin, a cellular
cofactor whose requirement for the completion of reverse transcription was previously established. It also
prevented the association of the reverse transcription complex with the cytoskeleton.
Conclusion: This work highlights the importance of PKC-delta during early steps of the replicative cycle of HIV-1 in
human macrophages.Background
Cells of the monocyte/macrophage lineage play a central
role in HIV-1 infection and pathogenesis. In addition,
macrophages play important roles for viral transmission
and dissemination [1,2]. Indeed, the primary infection is
initiated and carried out by macrophage-tropic viruses,
which use, in addition to CD4, the CCR5 co-receptor.
Macrophages are also one of the main reservoirs of
HIV-1. This latter property is related to the lack of viral
cytopathic effects in macrophages which ensures their
survival when compared to infected CD4 positive lym-
phocytes [3-5]. Furthermore, current therapies that tar-
get HIV-1 replication are not as efficient in macrophages
as they are in lymphocytes [6]. As a consequence,
macrophages, in contrast to CD4 positive T cells, are not
depleted during the course of HIV-1 infection. Thus, a
better understanding of HIV-1 replication and the* Correspondence: contreras.xavier@gmail.com; bahraoui@cict.fr
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reproduction in any medium, provided the orfinding of efficient therapies for macrophages remain
major challenges.
In addition to using CCR5 as the co-receptor for entry
into its cellular targets, HIV-1 hijacks the underlying cel-
lular machinery. Interactions between the viral gp120
envelope glycoprotein, CD4 receptor, and CCR5 co-re-
ceptor trigger a signaling cascade, which is comparable
to that observed with their natural ligands. Initiated
through the G-alpha proteins, these signals mobilize
intracellular free calcium, translocate PKC, activate
Pyk2, FAK. Erk1/2, Rho GTPases, and decrease levels of
intracellular cAMP [7-12]. By facilitating the first steps
of HIV-1 entry and trafficking in target cells, they play
essential roles in the viral replicative cycle [9,13-19].
Among these pathways, PKC plays a critical role. In
cells, where HIV-1 replicates efficiently, PKC must be acti-
vated. PKC isozymes (probably alpha and beta), which are
activated by interactions between CCR5 and HIV-1, play a
major role in the rearrangement of the actin cytoskeleton
that is required for viral entry [9]. In addition to facilitat-
ing entry, via the phosphorylation of IκB (Inhibitor of NF-
κB), PKC stimulates Nuclear Factor κB (NF-κB) [20-22].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 PKC-delta is required for HIV-1 BaL replication in
human macrophages. (A) Macrophages (5×105) were pretreated for
30 min with Ro31-8220, an inhibitor of all PKCs, or by selective
inhibitors of certain PKC isozymes (rottlerin, PKC-delta inhibitor, Hispidin
PKC-beta inhibitor and Gö6976, PKC-alpha, betaI, and mu inhibitor) at
indicated concentrations. HIV-1 BaL infection (1 ng p24/ml) lasted 3 h.
After 3 days culture supernatants were collected and viral replication
assessed by the presence of p24 determined by ELISA. (B) 5x105
macrophages were preincubated with rottlerin for 24 h and then
cultured in rottlerin free medium for 24 h before infection to evaluate
cytotoxic effects of rottlerin (rottlerin + wash). As positive control, the
total inhibitory effect of rottlerin was evaluated as described in panel A.
Error bars represent 3 experiments with one donor. Results are
representative of experiments achieved in three different donors. (C)
HeLa LTR-beta-gal cells or (D) macrophages were preincubated with
siRNA against PKC-delta or scrambled siRNA for 2 days. Cells were then
infected with HIV-1 BaL (1 ng p24) for 3 h and washed. After 48 h, cells
were treated with X-gal and infection was assessed by counting beta-
gal positive blue cells using microscopy (C) or by quantifying p24 in
the supernatant (D). Western blot with anti PKC-delta antibodies is
shown as the control. (E) Macrophages (5x106) were infected with HIV-
1 BaL (1 ng p24/ml) or stimulated by PMA for 30 minutes, and the
activation of PKC isozymes was determined by analyzing PKC
translocation to the membrane. Membrane bound (M) and cytoplasmic
(C) proteins were extracted and separated by 10% SDS-PAGE. PKC-delta
and betaII isozymes were visualized by chemiluminescence using
specific antibodies for each isozyme. Homogeneity of protein extracts
was controlled by amido black staining of membranes. The purity of
membrane and cytoplasmic fractions was controlled by Western
blotting for SLC44A1 (membrane) and Hsp70 (cytoplasm). Results are
representative of three independent experiments.
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transcription [23]. PKC also activates AP-1 and NF-AT
[24,25] which also bind to the HIV-1 promoter. Moreover,
PKC can phosphorylate a number of viral proteins such as
p17Gag [26], Nef [27-29] and Rev [30], although the func-
tional role(s) for their phosphorylation is poorly
understood.
Eleven PKC isozymes have been described [31,32].
They have been classified depending mainly on their
mechanism of action. They differ also in their subcellu-
lar localization and substrate specificity. Different types
of cells express distinct PKC isozymes. Since PKC is trig-
gered via CCR5, it is critical to determine which PKC
isozymes are stimulated and their roles in the HIV-1
replicative cycle.
Of these, PKC-delta plays a central role in the differenti-
ation of monocytes, which resist HIV-1 infection [33,34],
to macrophages, which are permissive for infection
[35,36]. Indeed, macrophage differentiation induced by
monocyte colony stimulating factor (M-CSF) [37,38] or by
PMA [39] depends on PKC-delta, which also activates
NF-κB [38,40] and associates with vimentin in the cyto-
skeleton [41]. Additionally, the C2 domain of PKC-delta
contains an actin-binding site. This binding could be
involved in the redistribution of actin in neutrophils
[42,43]. Thus, PKC-delta is a very attractive cellular cofac-
tor for HIV-1 infection, particularly in macrophages. How-
ever, the expression of PKC-delta is not restricted to
macrophages. Thus, effects of PKC-delta, which are
addressed by this study, could be extrapolated to other cell
types such as T lymphocytes, where the cytoskeleton also
plays a critical role in the viral replicative cycle.
In this study, we characterized effects of PKC-delta on
HIV-1 replication in human macrophages and demon-
strated that it plays a critical role at an early step of
infection.
Results
PKC-delta plays a major role in HIV-1 BaL replication in
macrophages
To determine the role of PKC in viral replication, macro-
phages were infected with the R5-tropic HIV-1 BaL in the
presence or absence of chemical inhibitors of PKC. HIV-1
replication was assessed at day 3 post-infection using p24
ELISA (Figure 1A). Ro31-8220 (5 μM), which inhibits all
PKC isozymes, decreased greatly (94%) viral replication
(Figure 1A, lane 2). Interestingly, rottlerin (5 μM), a spe-
cific PKC-delta inhibitor [44], also blocked viral replica-
tion, whereas hispidin, a PKC-beta inhibitor, had little to
no effect (Figure 1A, lanes 3 to 6). In addition, Go6976,
which inhibits PKC-alpha, beta and gamma, had limited
effects on viral replication (Figure 1A, lanes 7 and 8).
These results suggest that PKC-delta plays an important
role in HIV-1 infection of macrophages. Moreover, as
Figure 2 Effects of rottlerin on viral entry. Macrophages (5× 105/ml)
were untreated or treated with rottlerin (5 μM) (A) for 30 minutes or
(B) 2hours. (A) Cells were then stained for CD4 or CCR5 and analyzed
by FACS. Dashed lines correspond to unstained cells, solid lines to
specific staining. (B) Cells were then transduced with equal MOI of
VSV-G- or JR-FL-pseudotyped vectors carrying a GFP reporter plasmid.
Two days later, GFP-positive cells were counted using microscopy.
Results are represented as relative levels of infection, with infected
control cells set to 100%. Error bars are from triplicates of a single
experiment. Results are representative of 3 independent experiments.
(C) Cell fusion was measured by syncytia formation in a co-culture of
cells expressing CD4 and CCR5 or gp120 and gp41, in the presence or
absence of PKC inhibitors rottlerin, hispidin, Ro318220, Co6976, or the
fusion inhibitor C34 as the control. (D), (E) and (F) Phase contrast
microscopy images of syncytia in a coculture of cells expressing either
CD4 and CCR5 or gp120 and gp41, in the presence of C34 (D),
rotllerin 10 μM (F) or without inhibitors (E). Arrows indicate syncytium
formation. (G) Macrophages were pretreated or not with rottlerin or
C34 fusion inhibitor for 30 minutes and infected with HIV-1 BaL for
3 h, washed and treated with trypsin. After extensive washing, cells
were lysed and p24 quantified using p24 ELISA.
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toxic at these concentrations (Additional file 1: Figure
S1A); and HIV-1 BaL replication was similar in macro-
phages pre-treated or not with rottlerin (5 μM) for 24 h,
and subsequently washed and cultured for an additional
24 h (Figure 1B and data not shown). Thus the effect of
rottlerin is reversible. Strikingly, the preincubation of
HeLa-CD4-CCR5-CXCR4 (HeLa-R5/X4) cells with in-
creasing concentrations of siRNA [45] or antisense oligo-
nucleotides targeting PKC-delta [46] inhibited viral
replication by 62 and 85%, respectively, while control
siRNA or sense oligonucleotides had little to no effect
(Figure 1C and Additional file 1: Figure S1B). Indeed at
these conditions, PKC-delta expression was suppressed
strongly by siRNA or antisense oligonucleotides (Figure 1C,
lower panels and Additional file 1: Figure S1C). Replication
of X4-tropic viral strain HIV-1 VN44 was also inhibited in
HeLa-R5/X4 pre-incubated with siRNA against PKC-delta
(Additional file 2: Figure S2). To further confirm the
effects of the PKC-delta knockdown on viral replication,
we infected primary human macrophages pre-incubated
with siRNAs against PKC-delta with HIV-1 BaL. We
observed a 60% inhibition of viral replication at conditions
in which PKC-delta expression was reduced by siRNA
(Figure 1D, lane 2). This inhibition was in agreement with
decreased levels of PKC-delta (Figures 1C and 1D, lower
panels). Altogether, these results demonstrate the import-
ance of PKC-delta in the HIV-1 replicative cycle in
macrophages.
Since PKC-delta plays an important role in viral replica-
tion, next, we sought to determine whether interactions
between HIV-1 BaL and the target cell activate this iso-
zyme. In unstimulated cells, PKC isoforms are localized to
the cytoplasm. However, following their activation, they
undergo conformational changes and translocate to the
membrane. Taking this finding into account, we followed
the activation of PKC-delta by its presence in cytoplasmic
and membrane fractions in macrophages, which were pre-
incubated with or without HIV-1 BaL. Figure 1E demon-
strates that following 30 min incubation with HIV-1 BaL
(1 ng p24), PKC-delta translocated to the membrane frac-
tion of macrophages (Figure 1E, compare lanes 2 and 4).
This activation was even stronger than that by PMA, a
phorbol ester, which is widely used for the activation of
PKC (Figure 1E, lanes 5 and 6). In contrast, in unstimu-
lated cells, PKC-delta was present only in the cytoplasm
(Figure 1E, compare lanes 1 and 2). On the contrary,
PKC-betaII did not translocate to the membrane after the
incubation with viral particles, but only after macrophages
were stimulation by PMA (Figure 1E, lanes 5 and 6).
Taken together these results demonstrate a critical role for
PKC-delta in viral replication. They also indicate that
interactions between viral particles and target macro-
phages lead to its activation.Inhibition of PKC-delta restricts HIV-1 replication at a
post-entry step
To determine the role(s) of PKC-delta on viral entry, we
first measured the expression of cell surface markers
required for interactions between HIV-1 and macro-
phages, i.e. CD4 and CCR5, by flow cytometry (Figure 2A).
Preincubation of macrophages with rottlerin (5 μM) had
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This result suggests that PKC-delta does not affect the ex-
pression of HIV-1 receptor or co-receptor. Next, macro-
phages were transduced in the presence or absence of
rottlerin with lentiviral vectors coding for GFP (Green
Fluorescent Protein) and pseudotyped with the envelope
glycoprotein of the M-tropic HIV-1 JR-FL or the VSV-G
protein. In addition to its wide tropism, the G protein of
VSV mediates virus entry by endocytosis in a pH
dependent manner. This situation is unlike that with the
HIV-1 envelope glycoprotein, which mediates virus entry
via a pH-independent mechanism. Cells transduced by
these vectors were analyzed for the expression of the GFP
gene. Figure 2B demonstrates that macrophages were
transduced successfully by both vectors. When these
experiments were performed in the presence of rottlerin
(5 μM) (Figure 2B), the number of GFP-positive cells was
similar to that found with VSV-G pseudotyped vectors in
the absence of this inhibitor. In contrast, when examined
under the same conditions, this number was strongly
reduced for HIV-1 JR-FL pseudotyped vectors (90% inhib-
ition). Thus, the inhibition of PKC-delta has a strong effect
on HIV-1 JR-FL, but not VSV-G pseudotyped viral parti-
cles. These results demonstrate that the mode of entry
determines the requirement for PKC-delta. Indeed, both
vectors have similar mechanism by which their RNA is re-
verse transcribed, integrated and expressed, but differ in
their mechanism of entry. Previous studies suggestedFigure 3 Quantitative PCR of RT products (cDNA) from HIV-1 BaL-inf
siRNA against PKC-delta. Macrophages (5x105 cells/well) were pretreated
PKC-delta for 3 days (B) and then infected with HIV-1 BaL (1 ng p24) for 3
infection, and DNA was analyzed by PCR. Amplification of the early (R-U5)
(qPCR). Three independent experiments with macrophages from three diffealready that, after entry via endocytosis, the viral genome
in the reverse transcription complex is released in close
proximity to the nucleus and thus does not require migra-
tion across regions of the cell such as the actin cortical
mesh [47]. Thus, both the mode of entry and early post-
entry steps are different in HIV-1 JR-FL and VSV-G pseu-
dotyped lentiviral vectors. To discriminate between these
two possibilities, we examined the formation of syncytia
between HeLa-R5/X4 and HeLa-gp120/gp41, which ex-
press the envelope from the R5 tropic HIV-1 ADA. Under
these conditions, rottlerin and other PKC inhibitors did
not block the fusion of membranes (Figures 2C-F). To de-
termine effects of PKC-delta inhibition on viral entry, we
also pretreated macrophages first with rottlerin and then
incubated them with HIV-1BaL for additional 3 hours at
37°C. To remove adsorbed viruses, cells were treated with
trypsin. We used levels of intracellular p24 (measured by
ELISA) as a marker of virus entry. Indeed, similar levels of
p24 were found in cells treated or not with rottlerin
(Figure 2G). As a control, to ensure that levels of p24 cor-
respond to intracellular antigen and not to adsorbed
viruses after trypsin digestion, we used a known inhibitor
of fusion, the C34 peptide [48]. In its presence, the virus
continues to bind to its receptors, but it becomes unable
to induce membrane fusion. As expected, levels of p24
dropped strongly in the presence of the C34 peptide, con-
firming the specificity of this assay (Figure 2G). Taken to-
gether, these results indicate that blocking PKC-delta doesected macrophages pretreated or not with rottlerin or accel
by rottlerin (5 μM) for 30 minutes (A) or with accel siRNAs against
h at 37°C and washed. Cells were then lysed at 12 h and 24 h after
and late (pol) products of RT was performed by quantitative PCR
rent donors gave similar results.
Figure 4 Actin cytoskeleton is altered by pretreatment of
macrophages by rottlerin (5 μM). Human macrophages were
treated for 24 h with rottlerin (5 μM, C), transfected with siRNAs to
PKC-delta (D) or left untreated (A and B) and then fixed with
formaldehyde (3.7%). Macrophages were then permeabilised with
Triton X-100 (0.2%) and stained with rhodamine-phalloidin before
mounting using moviol. Preparations were then observed by
confocal microscopy. Confocal images are representative of three
independent experiments. Arrows indicate stress fibers (A) and
pseudopods (B). (E) Quantitative results represent the percentage of
cells with proper actin cytoskeleton in the presence of different
inhibitors or after treatment with siRNA against PKC-delta.
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inhibition occurs at an early step in the viral replicative
cycle.
Inhibition of PKC-delta affects an early step of reverse
transcription
To determine effects of inhibiting PKC-delta on tran-
scription, HeLa-R5/X4 cells, which contain an integrated
LTR-beta-galactosidase reporter gene, were incubated in
presence of GST-Tat (Additional file 3: Figure S3). The
addition of rottlerin had only small effects on GST-Tat-
induced transactivation of the HIV-1 LTR. Similarly,
transduction of macrophages with VSV-G pseudotyped
lentiviral vectors encoding GFP under the control of
HIV-1 LTR led to equivalent levels of GFP expression in
the presence or absence of this inhibitor (Figure 2B).
These results suggest that inhibiting PKC-delta does not
affect HIV-1 transcription and gene expression.
Next, we analyzed early steps that follow the entry of
HIV-1 into macrophages. To this end, we pretreated
macrophages with rottlerin or siRNA against PKC delta
and harvested viral DNA at different times after the in-
fection (12 and 24 h). DNA was extracted and quantita-
tive PCR analyses were conducted with oligonucleotides
specific for early (R-U5) and late (pol) reverse transcrip-
tion (RT) products (Figure 3). Early RT products were
detected with all conditions (Figure 3). These results in-
dicate that this early step of RT is not blocked following
PKC-delta inhibition by rottlerin or knock-down by
siRNA. In contrast, PCR amplification of late (pol) RT
products was attenuated greatly after rottlerin treatment
(Figure 3A). We observed a 61% and 73% inhibition at
12 h and 24 h, respectively. Late RT products were also
reduced in siRNA-treated cells (Figure 3B). These results
suggest that inhibiting PKC-delta inhibits the synthesis
of late RT products in macrophages. Overall, these
results suggest that PKC-delta is required at the level of
early reverse transcription, soon after the initiation of
viral cDNA synthesis.
Inhibition of PKC-delta impairs the integrity of actin
cytoskeleton in human macrophages
Since interaction between the RT complex and actin cyto-
skeleton is necessary for the elongation of reverse tran-
scriptase [47], next we analyzed effects of rottlerin on the
organization of actin cytoskeleton. Macrophages were pre-
incubated with or without rottlerin for 24 h, and labeled
with phalloidin, a specific ligand of F-actin (the monomer
forming actin microfilaments), which was coupled to
rhodamine, a fluorescent probe. Cells were then observed
using confocal microscopy. As a control, untreated
macrophages contained a number of pseudopods, which
are projections of the cytoplasm towards the exterior of
the cell that result from cytoskeletal rearrangements ofactin (Figure 4A-B). In these untreated macrophages,
actin microfilaments organize in stress fibers (Figure 4A,
see arrow). However, in rottlerin-pretreated macrophages,
very few pseudopods (Figures 4C) were observed, and
they did not contain stress fibers (Figure 4C). Interest-
ingly, this effect was reversible. Thus, in cells that were
preincubated with rottlerin and then cultured without
the inhibitor, we observed the restoration of normal cyto-
skeleton (Figure 4E lane 3). Importantly, siRNA against
PKC-delta had similar effects on the actin cytoskeleton
as rottlerin, although to a lesser extent (Figures 4D and
4E, lane 6). In addition, inhibitors of other PKC isozymes
such as hispidin or go6976 had no major effects on actin
filaments (Figure 4E). Thus, these data indicate that inhi-
biting PKC-delta affects the integrity of the actin cyto-
skeleton in macrophages.
Since the reverse-transcriptase complex from the in-
coming virus interacts with actin microfilaments [49],
we hypothesized that inhibiting PKC-delta could lead to
its dissociation from the actin cytoskeleton. To address
this question, we fractionated cellular and cytoskeletal
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not with rottlerin and then infected with HIV-1 BaL. RT
(Figure 5A) or matrix proteins (Gag-MA) (Figure 5B)
were detected by Western blotting. In cells infected with
HIV- or VSV-G-pseudotyped lentiviral vectors, RT was
found in the membrane and cytoskeletal fractions
(Figure 5A). However, RT was not found in the cytoskel-
etal fraction following the pre-treatment with rottlerin.
Similar results were obtained using the Gag-MA as a
marker (Figure 5B). Additionally, using cytochalasin D
(CCD) as a control to disrupt actin polymerization, the
Gag-MA was also not found in the cytoskeletal fraction.
Taken together, these results suggest that PKC-delta is
required for cytoskeletal integrity, which is essential for
early steps in viral replication.
Discussion
It was previously shown that PKC can be stimulated via
interaction between CCR5 and gp120 [9]. This activation
facilitates HIV-1 replication at different steps of its replica-
tive cycle including entry, integration and gene expression
[9,44,50,51]. However, these studies did not investigate thor-
oughly the role of different PKC isozymes in macrophages.
For this reason, we investigated the involvement of PKC-
delta, which plays an important role in the differentiation of
macrophages, in HIV-1 replication. Our work was per-
formed using complementary approaches including the
chemical inhibitor rottlerin, specific antisense oligonucleo-
tides, and specific siRNA. We demonstrated for the first
time that HIV-1 is able to activate PKC-delta in macro-
phages. Importantly, we demonstrated that PKC-delta is
critical for the replication of HIV-1 in human macrophages.Figure 5 Rottlerin reduces cytoskeletal association of HIV-1 RT comp
rottlerin (Rott) and then infected with HIV-1 BaL (50 ng p24) or VSV-G-pseu
(Cs) fractions were obtained and the presence of HIV-1 RT was assessed by
cytoskeletal fractions was analyzed by Western blotting for control proteins
pretreated with rottlerin or cytochalasin D (CCD) and then infected with H
nuclear (N) fractions were obtained, and the presence of Gag-MA was asse
bound, cytoskeletal and nuclear fractions was analyzed by Western blottingSeveral steps of the viral replicative cycle were analyzed
to identify the one that was affected by this inhibition.
Our results indicate that there is no block to viral entry
upon inhibiting PKC-delta. Indeed, the expression of viral
receptor (CD4) and co-receptor (CCR5) was not altered.
Nevertheless, a recent study demonstrated that inhibiting
PKC-alpha and/or beta could reduce the expression of
these surface molecules in CD4 T lymphocytes [9]. It is
thus possible that different PKC isozymes serve different
functions in different cellular contexts. Further supporting
our data, in the presence of PKC inhibitors, fusion oc-
curred normally as assessed by syncytia formation in co-
cultures with HeLa cells expressing R5/X4 and gp120/
gp41 from HIV-1 Lai or HIV-1 ADA. This latter finding
was confirmed by quantifying levels of intracellular p24
after incubating macrophages with HIV-1 ADA in the
presence or absence of PKC inhibitors. All these studies,
including levels of receptor/co-receptor and membrane
fusion, suggest that the step of entry was not affected by
inhibiting PKC-delta.
We also demonstrated that later steps, such as transcrip-
tion, were not affected as demonstrated by the ability of
Tat to activate the HIV-1 LTR similarly in the presence or
absence of PKC inhibitors. This lack of effect of PKC-delta
inhibitors on transcription was also confirmed with the
expression of LTR-GFP from cells treated with rottlerin
and transduced with VSV-G-pseudotyped vectors. Indeed,
the transduction of macrophages with VSV-G-pseudo-
typed, but not with HIV-1 JR-FL lentiviral vectors, was in-
sensitive to PKC-delta inhibition. VSV-G pseudotyped
vectors use an alternative pathway for RTC (RT com-
plexes) delivery to the cytosol and thus bypass HIV-lexes. (A) Macrophages (5x106) were left untreated or pretreated with
dotyped vector (10 ng p24). Membrane bound (M) and cytoskeletal
Western blotting (upper panels). Purity of membrane bound and
(bottom panels). (B) Macrophages (5x106) were left untreated or
IV-1 BaL (50 ng p24). Membrane bound (M), cytoskeletal (Cs) and
ssed by Western blotting (upper panels). The purity of membrane
for control proteins (bottom panels).
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PKC-delta inhibitor thus indicates clearly that early steps
of retroviral replicative cycle are the major targets of PKC-
delta inhibition.
To analyze further, we used Q-PCR and demonstrated
that the inhibition of PKC-delta affected a step prior to
the first strand transfer, but following initiation of RT.
Thus, the major step altered by PKC-delta inhibition
occurs early in RT. Several reports revealed that the
actin cytoskeleton of the target cell plays an important
role in the early steps of replication [52]. Indeed, the
interaction between RT complexes and actin is not only
essential for efficient RT, but also for the transport of
preintegration complexes to the nucleus [47,53,54]. In-
deed, pretreatment of cells with cytochalasin D (CCD),
an inhibitor of actin polymerization, prevents the infec-
tion by HIV-1. Because effects of PKC-delta inhibitors
on HIV-1 replication appeared to occur at a post entry
step, we also analyzed the actin cytoskeleton. Indeed, the
C2 domain of PKC-delta contains an actin-binding site,
which could be involved in the redistribution of actin in
neutrophils [42,43]. Accordingly, we demonstrated that
rottlerin and siRNA against PKC-delta altered the actin
cytoskeleton in macrophages, which is in agreement
with previous studies on PKC-delta.
Correlated to the impairment of the actin cytoskeleton,
we demonstrated that RT and p17 Ma proteins in the in-
coming RT complex, which are used frequently as markers
to monitor the RT complex, did not co-fractionate with
the cytoskeleton when PKC-delta was inhibited. Indeed,
several additional lines of evidence demonstrated a link
between actin cytoskeleton and HIV-1 replication. First, a
block at the level of early RT was previously reported
using cytochalasin D (CCD), an inhibitor of actin cytoskel-
eton polymerization [47,55]. Second, viral particle-
mediated induction of a signaling pathway via CXCR4 is
required for infection of resting T cells [56-58]. In these
cases, cofilin phosphorylates actin and participates in its
redistribution, which overcomes the restriction related to
cortical actin in resting T cells. Thirdly, Komano et al.
demonstrated that inhibiting Arp 2/3, which is involved in
actin polymerization, also restricts viral replication at an
early stage in T cells [59]. Finally, Naghavi et al. implicated
Moezin, which helps to tether cellular membranes to actin
as being critical for early steps of viral replication [60].
Thus, our studies suggest that PKC-delta is a major signal-
ing intermediary, which is activated by the virus to re-
arrange the actin network and thus facilitating early steps
in the viral replicative cycle, particularly the RT step, in
macrophages. Interestingly, recent studies have demon-
strated the importance of a shallow endocytic pathway for
HIV-1 entry and fusion [61]. Actin could thus play an im-
portant role in the completion of fusion after endocytosis.
However, our VSV-G-pseudotyped vectors were notaffected when PKC-delta was inhibited. Similar results
were reported by Burkinskaya et al. who demonstrated
that cytoskeletal impairment by CCD inhibits reverse
transcription after entry of HIV-1, but not VSV-G pseudo-
typed vector. Thus, there is a difference between HIV-
and VSV-G-mediated entries that requires PKC-delta and
actin cytoskeleton integrity. It is possible that PKC-delta is
critical only when fusion occurs independently of pH,
while it is not required when fusion occurs under low pH
conditions in late endosomes. It could i) favor fusion and
uncoating which involve both viral and cellular factors, ii)
allow transport of RTCs to permissive compartments con-
taining cellular factors required for RT, and iii) trigger ac-
tivation of RTCs by interaction with actin. However the
exact mechanism remains to be clarified.
Of note, viral nucleocapsid and integrase also interact
with actin [62,63]. Both of these proteins and Vpr are
part of the incoming reverse transcriptase complex.
Macrophages are a major target of HIV-1 infection,
due to their high levels of expression of CCR5 and their
persistence in infected individuals. Macrophages are
residents of different organs and tissues, including the
central nervous system, and thus can be found in differ-
ent microenvironments in which regular therapies may
be less effective than in circulating CD4+ T cells. In
these cells, pharmacokinetics and therapeutic efficiencies
are understudied areas of research. Understanding better
viral replication in macrophages could lead to the devel-
opment of improved therapies in the future.
Conclusions
This work shows that PKC-delta is activated following
interaction between HIV-1 and human primary macro-
phages and plays a major role in viral replication. PKC-delta
seems to play a role in early steps of the viral replicative
cycle, allowing completion of reverse transcription. Our
data suggest that this is due to a role of PKC-delta on the
organization of proper actin cytoskeleton.
Methods
Cell culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from Buffy coats of healthy HIV-negative donors in
a Ficoll density gradient (Pharmacia, Piscataway, NJ).
PBMCs were then plated at a density of 106 cells per well
in 24-well Primaria (Becton Dickinson, Rutherford, NJ)
tissue culture plates. Monocytes were isolated by adher-
ence, after 45 minutes incubation in Iscove medium sup-
plemented with human AB serum (10%). Monocytes were
then washed 3 times with HBSS and cultivated during
7 days in Iscove medium supplemented with 10% Fetal
Calf Serum (FCS), penicillin (100 units/ml) and strepto-
mycin (100 pg/ml) at 37°C, 5% CO2, in a humid atmos-
phere so that macrophages can differentiate. M-CSF
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Macrophages are 94% pure as tested by FACS with anti-
CD14 antibody.
Chemical inhibitors
Ro31-8220, a PKC inhibitor, rottlerin, a PKC-delta in-
hibitor, Hispidin, a PKC-beta inhibitor, Go6976, inhibitor
of calcium dependent PKC izozymes alpha and beta1
and of PKCmu and cytochalasin D, an inhibitor of actin
polymerization, have been obtained from Calbiochem.
SiRNAs
Validated siRNA to human PKC-delta (Cat# sc-36253)
[45,64] and control siRNA (Cat# sc-37007) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA)
and transfected in HeLa cells using siRNA transfection
reagent from Santa Cruz Biotechnology (Cat# sc-29528).
Accel siRNAs to human PKC-delta (Cat# A-003524-16-
0005) and control accel siRNA (Cat# D-001910-01-05)
were purchased from Thermo scientific and introduced in
human primary macrophages without transfection re-
agent, by simple incubation for 2 days before infection
with HIV-1 BaL. Targetting sequence for siRNA to PKC-
delta is GUUCUGUGCAAAGACUU.
The following phosphorothioate oligonucleotides
sense GCCCCACCATGGCGCCGTTC and antisense
GAACGGCGCCATGGTGGGGC (target region on
mRNA PKC −8 to+ 12) specific to PKC-delta were
synthesized by Genset Oligos (Genset SA). Antisense oli-
gonucleotides were previously assessed for their specificity
[46] and used as previously described [46].
Infection
HeLa-R5/X4 (2.105 cells) were cultured in 12 well plates
and transfected with siRNA control or siRNA PKC-delta
(see above) using siRNA transfection reagent from Santa
Cruz Biotechnology (Cat# sc-29528) at 10 or 30 nM.
After 48 h, cells were infected with HIV-1 BaL or HIV-1
VN44 in DMEM 2% FCS and washed 2 times after 3
hours with DMEM. Cells were then cultivated in DMEM
10% FCS 1% PS. After 24 h, infection was scored via
LTR-transactivation using X-gal coloration.
Macrophages (5.105 cells) were cultured in 12 well
plates and transfected with Accel siRNA control or
Accel SiRNA PKC-delta at 10-6 M (Thermofisher, see
above). After 48 h, cells were infected with HIV-1 BaL in
DMEM 2% FCS and washed 2 times after 3 hours with
DMEM. Macrophages were then cultivated in DMEM
10% FCS 1% PS. After 3 days, infection was assessed by
detecting p24 in the supernatant using ELISA.
Extraction of membrane and cytoplasmic proteins
After treatment of macrophages with HIV-1 BaL, 1 ng
p24, macrophages (5.106) were harvested at 30 minutesor 1 h and lysed at 4°C in 100 μl of hypotonic buffer A
(20 mM Tris HCl, 2 mM EDTA, 1 mM DTT, 10 μg/ml
leupeptin, 1 mM PMSF; pH 7,5) by repeated aspirations
through a syringe fitted with a 21 Gauge needle. After
the addition of 200 μl of fresh buffer B (20 mM Tris
HCl, 2 mM EDTA, 1 mM DTT, 10 μg/ml leupeptine,
1 mM PMSF, 0.33 M sucrose; pH 7.5), the lysate was
centrifuged at 100,000 g, 4°C, for 40 min. The super-
natant, corresponding to the cytoplasmic fraction, was
collected; proteins were quantified by the Bradford assay
and stored at −20°C. The pellet, corresponding to the
membrane fraction, was solubilised in 50 μl of fresh B
buffer containing 1% of Triton X-100, sonicated (1 min,
power 2.5), and the amount of proteins quantified and
stored at −20°C.
Extraction of total proteins
After macrophage treatment with HIV-1 BaL, 1 ng p24,
during 30 minutes or 1 h, macrophages (2.106) were har-
vested, centrifuged, and the pellet lysed in 200 μl of PBS
1% NP-40. The amount of proteins was quantified by the
Bradford assay and then proteins were stored at −20°C.
Extraction of cytoplasmic, membrane and cytoskeleton
fractions
Macrophages (5.106 cells) were lysed and cytoplasmic, mem-
brane and cytoskeleton fractions obtained as previously
described [47]. Anti-RT antibory is from abcam (ab63911)
and anti-gagMA was obtained from the NIH reagents
program.
Western blotting
Identical amounts of proteins (10 μg) were separated on
SDS-PAGE gel and then transferred to a nitrocellulose
membrane. Immunoblotting was conducted by using ei-
ther anti-PKC isozyme antibodies (anti-PKC-delta and anti
PKC-betaII) at the 1:1000 dilution (Santa-Cruz biotechnol-
ogy). Membranes were blocked in 5% milk, Tris-buffered
saline, 0.05% Tween 20 (TTBS) for 1 h, washed 4 times
with TTBS, and incubated with the primary antibody for
2 h. Immuno-reactive bands were detected by 2 h incuba-
tion with secondary antibodies directed against rabbit
immunoglobulins conjugated with peroxydase (1:1000)
(DAKO A/S, Roskilde, Denmark). Bands were visualized
on film after incubation of the membranes with a chemilu-
minescent substrate (Pierce, Rockford, IL).
Lentiviral vectors
293 T cells (2.5.106) were cultured on a 150 mm Petri
dish in DMEM 10% FCS, penicillin (100U/ml) and
streptomycin (10 pg/ml), supplemented with L-glutamine
(2 mM) for 24 h. Cells were then cotransfected by the
phosphate calcium method, with 30 μg of gag-pol plasmid
coding for capsid proteins and HIV-1 enzymes, 10 μg of
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tiviral vector with GFP driven by CMV. The medium was
changed 10 h after cotransfection. Supernatant was har-
vested 72 h after contransfection and centrifuged 15 min-
utes at 2500 rpm. Supernatant was filtered through a
0.22 μm filter and then ultracentrifuged 90 minutes at
50,000 g. The pellet was finally resuspended in 100 μl PBS.
Transduction
Macrophages, isolated as previously described in 24 well
plates, were preincubated with or without rottlerin dur-
ing 2 hours and then incubated 3 h at 37°C in 250 μl of
Iscove medium 2% FCS containing 50 μl of VSV-G/GFP
vector per well, in presence or absence of inhibitors.
After 2 washes with PBS, cells were cultivated in Iscove
medium, 10% FCS. After 2 days, cells were visualized
with a fluorescence microscope.
Q-PCR
5×105 macrophages/well in a 24-well plate were incubated
for 3 h at 37°C in the presence of HIV-1 BaL virus (1 ng
p24/ml) pretreated with DNase I. Cells were then washed
with HBSS and Iscove medium, 10% FCS, 1% penicillin/
streptomycin was added. Cells were then washed with
HBSS at different times after infection. DNA was then
extracted (Qiagen). For the detection of early (R-U5) and
late (pol) reverse transcripts, DNA was amplified with the
appropriate primers at 70°C in a LightCycler (Roche) with
SYBR Green following the manufacturer’s recommenda-
tions. Viral DNA was normalized by cellular genomic
GAPDH. Primers sequence: Strong-stop: (1) agcctgg-
gagctctctggcta and (2) ccagagtcacacaacagacgg; Late: (1) and
(3) cgcttcagcaagccgagtcct, GAPDH gene: (4) : ctctgacttcaa-
cagcgac and (5) : tctctcttcctcttgtgctc
Actin cytoskeleton analysis
Macrophages (5.105 cells/well) were resuspended and
placed in wells containing a glass slide. After two cycles
of adherence, macrophages were washed 2 times with
PBS, and then fixed with PBS medium 3.7% formalde-
hyde for 10 minutes at room temperature. After two
more washes with PBS, macrophages were permeabilised
by a 5 min incubation in the presence of 0.1% TRITON
X-100. Two washes with PBS were performed, then cells
were blocked with PBS 1% BSA for 30 min to avoid
non-specific labeling. Cells were then labeled with phal-
loidine-rhodamine (1U/well/200 μl of PBS 1% BSA, Mo-
lecular Probes) for 20 minutes at room temperature.
Macrophages were washed two more times with PBS
and then mounted on cover slide using moviol and
placed at 4°C until observation. Macrophages labeled
with phalloidine-rhodamine were observed under a con-
focal microscope equipped with a 568 nm laser to excite
the probe. 50 cells per slide were counted on at least 2different slides per condition. Cells with clear pseudo-
podes were counted as positive while cells without pseu-
dopodes or with small rare pseudopodes were negative.
All results were normalized to control cells (100%).
Syncytia formation
HeLa-R5/X4 (10000 cells) were cocultured with HeLa-
gp120/gp41LAI or HeLa-gp-120/gp41ADA (10000 cells)
in 96-well plates in the presence of various concentra-
tions of each inhibitor. After 20 h, syncytia were scored
by contrast phase microscopy.
Additional files
Additional file 1: Figure S1. (A) Macrophages were incubated with
different chemical inhibitors (left panel) or increasing doses of rottlerin for
72h or DMSO as negative control. Cell viability was assessed by trypan blue
staining. (B) Macrophages were incubated in the presence of sense or
antisense oligonucleotides for 2 days and then infected with HIV-1 BaL (1ng
p24) for 2 h. Macrophages were then washed and supernant collected after
72 h. P24 was quantified by ELISA and percentage of inhibition measured.
(C) Western blot showing expression of PKC-delta in cell extracts from
macrophages incubated with sense or antisense oligonucleotides for 48 h.
As control, the effect of antisense PKC-delta was tested on the expression of
PKC-alpha. In each case, antibodies specific to each PKC isoform were used
in Western blot labeling.
Additinal file 2: Figure S2. HeLa CD4-CXCR4-CCR5 cells were left
untreated or transfected with control siRNA (30nM) or siRNA to PKC-delta (10
or 30nM) and then infected with HIV-1 VN44 X4-tropic virus (1ng p24) for 3 h
then washed. 48h later, cells were incubated in the presence of X-gal and
infection was assessed by counting beta-gal positive cells by microscopy.
Additional file 3: Figure S3. HeLa-R5/X4 cells with integrated LTR-beta-gal
were preincubated or not with rottlerin (5μM) for 30 min and then left
untreated or transduced using Gst-Tat (5μM). After 24 hours, beta-gal positive
cells were scored using X-Gal by microscopy. LTR transactivation is relative
and was set to 100% for Gst-Tat treated cells in absence of rottlerin.Competing interests
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